| Literature DB >> 33297994 |
Dongwoo Yu1, Sang Woo Kim1, Ikchan Jeon2.
Abstract
BACKGROUND: There are still controversies regarding the treatment and outcomes in culture-negative pyogenic vertebral osteomyelitis (PVO). The purpose of this study is to investigate the antimicrobial therapy, assessment of therapeutic response, and outcome of culture-negative PVO compared to culture-positive PVO.Entities:
Keywords: Vertebral osteomyelitis, Pyogenic, Negative culture, Antibiotics, Lumbar
Mesh:
Substances:
Year: 2020 PMID: 33297994 PMCID: PMC7726898 DOI: 10.1186/s12879-020-05669-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical data
| CN group ( | CP group ( | Total ( | ||
|---|---|---|---|---|
| Age [year] | 65.41 ± 11.60 | 61.83 ± 13.76 | 0.570 | 64.73 ± 11.61 (42-84) |
| Male sex | 27 (65.9%) | 17 (53.1%) | 0.337 | 44 (60.3%) |
| BMI | 22.97 ± 3.25 | 24.27 ± 3.75 | 0.120 | 23.54 ± 3.52 |
| Underlying disease | ||||
| Diabetes mellitus | 14 (34.1%) | 7 (21.9%) | 0.304 | 21 (28.8%) |
| Rheumatic disease | 3 (7.3%) | 1 (3.1%) | 0.626 | 4 (5.5%) |
| Liver cirrhosis | 2 (4.9%) | 0 (0%) | 0.501 | 2 (2.7%) |
| Chronic kidney disease | 1 (2.4%) | 0 (0%) | 1.000 | 1 (1.4%) |
| Alcohol | 13 (31.7%) | 4 (12.5%) | 0.092 | 17 (23.3%) |
| Smoking | 15 (36.6%) | 6 (18.8%) | 0.121 | 21 (28.8%) |
| History of spinal procedures | 27 (65.9%) | 18 (56.3%) | 0.471 | 45 (61.6%) |
| Epidural injection | 25 (55.6%) | 18 (50.0%) | 0.659 | 43 (53.1%) |
| Acupuncture [oriental medicine] | 10 (24.4%) | 4 (12.5%) | 0.242 | 14 (19.2%) |
| Fever [°C, > 37.3] | 11 (26.8%) | 8 (25.0%) | 1.000 | 19 (26.0%) |
| Neurological symptom | 17 (41.5%) | 20 (62.5%) | 0.100 | 37 (50.7%) |
| Features of PVO | ||||
| Extent of affected lesion [level] | 1.49 ± 0.93 (1-5) | 2.09 ± 1.28 (1-5) | 0.022 | 1.75 ± 1.13 (1-5) |
| Epidural abscess | 18 (43.9%) | 27 (84.4%) | 0.001 | 45 (61.6%) |
| Psoas abscess | 17 (41.5%) | 13 (40.6%) | 1.000 | 30 (41.1%) |
| Paraspinal abscess | 27 (65.6%) | 23 (71.9%) | 0.612 | 50 (68.5%) |
| Duration of hospital stay [days] | 50.32 ± 19.96 (21-120) | 62.88 ± 26.04 (26-143) | 0.022 | 55.82 ± 23.51 (21-143) |
| Follow up period [months] | 18.00 ± 11.16 (6-42) | 16.38 ± 12.48 (6-63) | 0.560 | 17.29 ± 11.70 (6-63) |
| Recurrence | 3 (7.3%) | 2 (6.3%) | 1.000 | 5 (6.8%) |
Data are presented as the mean ± standard deviation or frequency, CN culture negative, CP culture positive, BMI body mass index, PVO pyogenic vertebral osteomyelitis, a p value between group CN and CP, p values of < 0.05 were considered statistically significant.
Microbiologic findings
| Factors | Values |
|---|---|
| Causative bacterial identification | 32/73 (43.8%) |
| Blood culture | 8 (25.0%) |
| Tissue culture of CT-guided needle biopsy on PVO lesion | 5 (15.6%) |
| Tissue culture of open biopsy on PVO lesion | 10 (31.3%) |
| Both (blood and tissue cultures) | 9 (28.1%) |
| Positive culture rates depending on the methods | |
| Blood culture | 17/73 (23.3%) |
| Tissue culture of CT-guided needle biopsy on PVO lesion | 7/37 (18.9%) |
| Tissue culture of open biopsy on PVO lesion | 17/36 (47.2%) |
| Microbiological findings ( | |
| Gram-positive bacteria | 26 (81.3%) |
| | 13 (40.6%) |
| MSSA | 10 (31.2%) |
| MRSA | 3 (9.4%) |
| | 4 (12.5%) |
| | 6 (18.8%) |
| | 2 (6.3%) |
| Othersa | 4 (12.5%) |
| | 3 (9.4%) |
| Gram-negative bacteria | 6 (18.8%) |
| | 2 (6.3%) |
| | 1 (3.1%) |
| | 2 (6.3%) |
| | 1 (3.1%) |
Data are presented as frequency, PVO pyogenic vertebral osteomyelitis, MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, a Streptococcus viridians, Streptococcus pneumoniae, and Streptococcus bovis
Regimens of antibiotics
| CN group ( | CP group ( | Total ( | ||
|---|---|---|---|---|
| Parenteral antibiotics | 41 (100%) | 32 (100%) | – | 73 (100%) |
| β-Lactam | 15 (36.6%) | 11 (34.4%) | 1.000 | 26 (35.6%) |
| 1st generation cephalosporin | 10 (24.4%) | 3 (9.4%) | 0.128 | 13 (17.8%) |
| 3rd generation cephalosporin | 4 (9.8%) | 2 (6.3%) | 0.689 | 6 (8.2%) |
| Nafcillin | 1 (2.4%) | 6 (18.8%) | 0.039 | 7 (9.6%) |
| β-Lactam ± others a | 6 (14.6%) | 5 (15.6%) | 1.000 | 11 (15.1%) |
| Glycopeptide ± others b | 11 (26.8%) | 12 (37.5%) | 0.447 | 23 (31.5%) |
| Quinolone | 9 (22.0%) | 1 (3.1%) | 0.036 | 10 (13.7%) |
| Others c | 0 (0%) | 3 (9.4%) | 0.080 | 3 (4.1%) |
| Oral antibiotics | 33 (77.8%) | 12 (38.9%) | 0.001 | 49 (60.5%) |
| β-Lactam | 7 (17.1%) | 1 (3.1%) | 0.072 | 8 (11.0%) |
| Quinolone | 26 (63.4%) | 11 (34.4%) | 0.019 | 37 (50.7%) |
CN culture negative, CP culture positive, Data are presented as frequency, a β-lactamase inhibitor, aminoglycoside, b Gentamicin and tazime, c Carbapenem, prepenem, and linezoid, # p value between the CN and CP groups, p values of < 0.05 were considered statistically significant
Comparison of antibiotic treatment between the CN and CP groups
| CN group ( | CP group ( | Total ( | ||
|---|---|---|---|---|
| Use of antibiotics before tissue-culture | 32/41(78.0%) | 20/32 (62.5%) | 0.194 | 52/73 (71.2%) |
| Duration of antibiotic treatment (days) | ||||
| Total [parenteral + oral] | 101.17 ± 52.84 (31-209) | 84.19 ± 50.29 (25-198) | 0.168 | 93.73 ± 52.08 (25-209) |
| Parenteral | 45.88 ± 16.14 (17-95) | 57.31 ± 24.39 (25-144) | 0.019 | 50.89 ± 20.82 (17-144) |
| Oral | 55.29 ± 47.40 (0-166) | 26.84 ± 41.10 (0-126) | 0.009 | 42.82 ± 46.66 (0-166) |
| Incidence of using oral antibiotics | 31/41(75.6%) | 14/32, (43.8%) | 0.001 | 45/73 (61.6%) |
Data are presented as the mean ± standard deviation or frequency, CN culture negative, CP culture positive, # p value between group CN and CP, p values of < 0.05 were considered statistically significant
Logistic regression analysis in the correlation between the causative bacterial identification (culture positive) and variable clinical variables
| Clinical variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Open surgical biopsy | 3.31 | 1.26-8.71 | 0.015 | |||
| Extent of affected lesion | 1.65 | 1.06-2.58 | 0.027 | |||
| Epidural abscess | 6.90 | 2.22-21.49 | 0.001 | 6.57 | 2.00-21.57 | 0.002* |
| Initial CRP | 1.08 | 1.02-1.14 | 0.009 | |||
| Initial back VAS | 2.00 | 1.21-3.33 | 0.007 | 1.95 | 1.13-3.38 | 0.017* |
OR odds ratio, CI confidential interval, CRP C-reactive protein (normal range < 0.5 mg/dL), VAS visual analog scale, p values of < 0.05 were considered statistically significant
Changes of ESR/CRP and VAS score of back pain during 3 months since antimicrobial therapy started
| CN group ( | CP group ( | Total ( | ||
|---|---|---|---|---|
| ESR | ||||
| Initial (at diagnosis) | 66.88 ± 31.89 | 72.44 ± 31.89 | 0.462 | 69.32 ± 31.79 |
| 1 week | 70.98 ± 33.81 | 74.31 ± 26.84 | 0.649 | 72.44 ± 30.79 |
| 1 month | 55.29 ± 29.94 | 61.31 ± 31.07 | 0.405 | 57.93 ± 30.37 |
| 3 months | 30.51 ± 19.65+ | 42.81 ± 31.44+ | 0.058 | 35.90 ± 26.03 |
| CRP | ||||
| Initial (at diagnosis)* | 9.21 ± 7.43 | 15.17 ± 10.32 | 0.005 | 11.83 ± 9.24 |
| 1 week | 5.67 ± 5.75 | 6.97 ± 5.74 | 0.339 | 6.24 ± 5.74 |
| 1 month | 1.89 ± 2.05 | 2.26 ± 2.75 | 0.516 | 2.06 ± 2.37 |
| 3 months | 0.58 ± 0.99+ | 0.79 ± 1.29+ | 0.427 | 0.67 ± 1.13 |
| VAS score of back pain | ||||
| Initial (at diagnosis)* | 7.41 ± 0.92 | 8.13 ± 1.13 | 0.004 | 7.73 ± 1.07 |
| 1 week | 5.73 ± 1.18 | 5.63 ± 1.39 | 0.724 | 5.68 ± 1.27 |
| 1 month | 4.32 ± 1.13 | 4.47 ± 1.27 | 0.591 | 4.38 ± 1.19 |
| 3 months | 3.37 ± 0.92+ | 3.44 ± 1.27+ | 0.780 | 3.39 ± 1.08 |
| When discontinuation of parenteral antibiotics | ||||
| ESR | 44.85 ± 24.99 | 40.31 ± 22.91 | 0.427 | 42.86 ± 24.05 |
| CRP | 0.89 ± 1.02 | 0.93 ± 1.37 | 0.907 | 0.91 ± 1.18 |
| VAS score of back pain | 3.98 ± 1.08 | 4.16 ± 1.05 | 0.476 | 4.05 ± 1.07 |
CN culture negative, CP culture positive, ESR erythrocyte segmentation rate (normal range < 25 mm/h), CRP C-reactive protein (normal range < 0.5 mg/dL), VAS visual analogue scale, # p value between group CN and CP, * There is statistical significant difference between the two groups (p < 0.01) +, There is statistical significant difference compared to initial value (p < 0.01), p values of < 0.05 were considered statistically significant